RecruitingPhase 3NCT07516769
Nicorandil as Anti-inflammatory in Rheumatoid Arthritis
Clinical Study Evaluating the Effect of Nicorandil as Anti-inflammatory and Immune Modulatory in Patients With Rheumatoid Arthritis
Sponsor
Tanta University
Enrollment
46 participants
Start Date
Nov 1, 2024
Study Type
INTERVENTIONAL
Conditions
Summary
This study aims to evaluate the possible efficacy and safety of nicorandil as anti-inflammatory in managing patients with active rheumatoid arthritis.
Eligibility
Min Age: 18 YearsMax Age: 70 Years
Inclusion Criteria2
- Patients with active rheumatoid arthritis (not in remission) according to American College of Rheumatology/European League Against Rheumatism (ACR/EULAR) i.e., 28 joints disease activity score (DAS-28) >2.6.
- Patients receiving the conventional DMARDs
Exclusion Criteria6
- Patients with heart disease (congestive heart failure, arrhythmia and ischemic heart disease), diabetes, active infection, and other illness except rheumatoid arthritis.
- Patients with severe renal and hepatic dysfunction. - Patients receiving biological DMARDs.
- Patients receiving oral prednisolone greater than 15mg/day.
- Patients with hypersensitivity to study medications.
- Patients using antioxidants.
- Pregnant and lactating females.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
DRUGNicorandil 10 MG Oral Tablet
Nicorandil 10 MG Oral Tablet
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07516769